Company Overview of 3SBio Inc.
3SBio Inc. offers research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also markets Intefen, a recombinant interferon alpha-2a product to treat carcinoma and viral infectious diseases; Inleusin, a recombinant human interleukin-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis; Iron Su...
No. 3 A1, Road 10
Shenyang Economy & Technology Development Zone
Founded in 2006
Key Executives for 3SBio Inc.
Co-Founder, Chairman, Chief Executive Officer, Chairman of Nominating Committee and Member of Investment Committee
Chief Financial Officer, Principal Accounting Officer and Member of Investment Committee
Chief Technology Officer, Vice President of R&D and Director
Vice President and Corporate Secretary
Compensation as of Fiscal Year 2014.
3SBio Inc. Key Developments
3SBio Seeks Acquisitions
May 27 15
3SBio Inc. filed an IPO in the amount of HKD 5.5 billion. It will use the proceeds to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market.
3SBIO Launches IPO
May 26 15
3SBIO Inc. launches an IPO of HKD 712 million IPO in Hong Kong to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market. 3SBIO plans to use 45%of the IPO proceeds to expand its portfolio of drugs through acquisitions, 15% to hire more sales staff and open offices around China, and another 15% for new production lines. The remainder would be spent on research and development and working capital.
3SBio Signs Exclusive Patent License Agreement for DIG-KT With PharmAbcine, Inc
Jan 15 15
3SBio Inc. announced that it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody (mAb) targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries